Traws Pharma (TRAW) Competitors $2.84 +0.06 (+2.35%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends TRAW vs. BLUE, CLNN, SRZN, TPST, RVPH, FBLG, ATHE, CELU, CVKD, and GBIOShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include bluebird bio (BLUE), Clene (CLNN), Surrozen (SRZN), Tempest Therapeutics (TPST), Reviva Pharmaceuticals (RVPH), FibroBiologics (FBLG), Alterity Therapeutics (ATHE), Celularity (CELU), Cadrenal Therapeutics (CVKD), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. bluebird bio Clene Surrozen Tempest Therapeutics Reviva Pharmaceuticals FibroBiologics Alterity Therapeutics Celularity Cadrenal Therapeutics Generation Bio bluebird bio (NASDAQ:BLUE) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment. Do analysts recommend BLUE or TRAW? bluebird bio currently has a consensus price target of $51.00, indicating a potential upside of 1,236.83%. Given bluebird bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe bluebird bio is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bluebird bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BLUE or TRAW more profitable? bluebird bio has a net margin of -565.74% compared to Traws Pharma's net margin of -62,294.25%. Traws Pharma's return on equity of 0.00% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets bluebird bio-565.74% -322.46% -53.17% Traws Pharma -62,294.25%N/A -822.38% Which has more risk and volatility, BLUE or TRAW? bluebird bio has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Does the media favor BLUE or TRAW? In the previous week, bluebird bio had 3 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for bluebird bio and 0 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.00 beat bluebird bio's score of 0.06 indicating that Traws Pharma is being referred to more favorably in the news media. Company Overall Sentiment bluebird bio Neutral Traws Pharma Positive Does the MarketBeat Community prefer BLUE or TRAW? bluebird bio received 1040 more outperform votes than Traws Pharma when rated by MarketBeat users. CompanyUnderperformOutperformbluebird bioOutperform Votes104070.70% Underperform Votes43129.30% Traws PharmaN/AN/A Do insiders & institutionals believe in BLUE or TRAW? 87.4% of bluebird bio shares are owned by institutional investors. Comparatively, 7.9% of Traws Pharma shares are owned by institutional investors. 1.4% of bluebird bio shares are owned by company insiders. Comparatively, 13.6% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, BLUE or TRAW? Traws Pharma has lower revenue, but higher earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobluebird bio$53.12M0.70-$211.91M-$37.40-0.10Traws Pharma$226K45.78-$18.95M-$141.56-0.02 Summarybluebird bio beats Traws Pharma on 10 of the 17 factors compared between the two stocks. Remove Ads Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.35M$7.11B$5.73B$8.09BDividend YieldN/A2.76%4.41%4.08%P/E Ratio-0.026.3024.2518.98Price / Sales45.78234.44400.8388.30Price / CashN/A65.6738.1134.64Price / Book0.226.596.904.36Net Income-$18.95M$141.83M$3.19B$246.83M7 Day Performance2.68%2.31%2.16%3.30%1 Month Performance-39.57%-7.20%0.55%-7.94%1 Year PerformanceN/A-5.11%14.13%3.81% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma1.0637 of 5 stars$2.83+2.3%N/AN/A$10.35M$226,000.00-0.0217BLUEbluebird bio2.7379 of 5 stars$3.96+5.6%$48.10+1,114.6%-86.0%$38.50M$53.12M-0.11520Upcoming EarningsAnalyst ForecastCLNNClene3.4464 of 5 stars$4.56+2.9%$55.25+1,111.6%-46.3%$37.97M$421,000.00-0.86100Upcoming EarningsSRZNSurrozen2.2766 of 5 stars$11.60+0.1%$38.50+231.9%-14.3%$37.70M$10M0.0080Gap UpTPSTTempest Therapeutics1.5804 of 5 stars$0.86+1.8%$26.00+2,940.9%-78.0%$37.31MN/A-0.5620RVPHReviva Pharmaceuticals3.5991 of 5 stars$1.10-0.9%$11.40+936.4%-62.3%$36.79MN/A-0.995Gap UpFBLGFibroBiologics1.6478 of 5 stars$1.00-2.0%$13.00+1,200.0%-90.7%$36.41MN/A0.0010ATHEAlterity Therapeutics2.4914 of 5 stars$4.03+2.3%$12.00+197.8%+137.7%$35.73MN/A0.0010Gap DownCELUCelularity0.1218 of 5 stars$1.49-3.9%N/A-68.0%$35.47M$48.20M0.00220CVKDCadrenal Therapeutics2.8208 of 5 stars$19.87+4.1%$32.00+61.0%N/A$35.43MN/A-2.984Earnings ReportGap DownGBIOGeneration Bio3.1554 of 5 stars$0.53+10.4%$7.33+1,283.6%-81.7%$35.40M$18.58M-0.24150Earnings ReportAnalyst ForecastHigh Trading Volume Remove Ads Related Companies and Tools Related Companies bluebird bio Competitors Clene Competitors Surrozen Competitors Tempest Therapeutics Competitors Reviva Pharmaceuticals Competitors FibroBiologics Competitors Alterity Therapeutics Competitors Celularity Competitors Cadrenal Therapeutics Competitors Generation Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 3/20/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 19th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
